Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
CALL
United States Antimony
UAMY
$799M
| $1.76M | ﹤0.01% |
+350,000
| New | +$2.75M |
|
3002
Anavex Life Sciences
AVXL
$303M
| $1.76M | ﹤0.01% |
493,172
+231,892
| +89% | +$1.42M |
|
|
AIOT
3003
PowerFleet Inc
AIOT
$421M
| $1.75M | ﹤0.01% |
329,774
+28,444
| +9% | +$146K |
|
3004
Prothena Corp
PRTA
$466M
| $1.75M | ﹤0.01% |
183,625
+85,550
| +87% | +$871K |
|
3005
Washington Trust Bancorp
WASH
$767M
| $1.75M | ﹤0.01% |
59,240
+9,354
| +19% | +$266K |
|
|
ARES.PRB
3006
Ares Management Corp 6.75% Series B Preferred Stock
ARES.PRB
$1.41B
| $1.75M | ﹤0.01% |
34,674
-73,483
| -68% | -$3.62M |
|
|
INN
3007
Summit Hotel Properties
INN
$656M
| $1.75M | ﹤0.01% |
358,604
+4,561
| +1% | +$23.9K |
|
3008
Ameresco
AMRC
$1.47B
| $1.74M | ﹤0.01% |
59,531
-75,334
| -56% | -$2.64M |
|
|
SEE
3009
DELISTED
Sealed Air
SEE
| $1.74M | ﹤0.01% |
42,060
-185
| -0.4% | -$7.16K |
|
3010
Unitil
UTL
$992M
| $1.74M | ﹤0.01% |
35,970
+6,302
| +21% | +$307K |
|
3011
First Mid Bancshares
FMBH
$1.39B
| $1.74M | ﹤0.01% |
44,568
+4,053
| +10% | +$154K |
|
|
BCAX
3012
Bicara Therapeutics
BCAX
$1.56B
| $1.74M | ﹤0.01% |
103,241
+55,093
| +114% | +$941K |
|
3013
CALL
NuScale Power
SMR
$4.04B
| $1.74M | ﹤0.01% |
+122,500
| New | +$3.5M |
|
3014
Gildan
GIL
$10.6B
| $1.73M | ﹤0.01% |
27,763
+16,109
| +138% | +$958K |
|
3015
Deluxe
DLX
$1.11B
| $1.73M | ﹤0.01% |
77,419
+14,943
| +24% | +$301K |
|
3016
Inhibrx
INBX
$1.42B
| $1.73M | ﹤0.01% |
21,879
+8,411
| +62% | +$573K |
|
3017
Beazer Homes USA
BZH
$874M
| $1.73M | ﹤0.01% |
85,116
+22,767
| +37% | +$506K |
|
|
GPGI
3018
GPGI Inc
GPGI
$3.75B
| $1.73M | ﹤0.01% |
89,476
+27,014
| +43% | +$539K |
|
3019
Tompkins Financial
TMP
$1.45B
| $1.72M | ﹤0.01% |
23,742
+2,409
| +11% | +$165K |
|
3020
Arbutus Biopharma
ABUS
$906M
| $1.72M | ﹤0.01% |
356,684
+72,354
| +25% | +$325K |
|
3021
Central Pacific Financial
CPF
$1B
| $1.71M | ﹤0.01% |
54,979
+8,021
| +17% | +$242K |
|
3022
DXC Technology
DXC
$1.79B
| $1.69M | ﹤0.01% |
115,386
+2,883
| +3% | +$39.6K |
|
3023
Mizuho Financial
MFG
$134B
| $1.69M | ﹤0.01% |
+230,885
| New | +$1.58M |
|
|
NPKI
3024
NPK International
NPKI
$1.18B
| $1.69M | ﹤0.01% |
141,582
+30,542
| +28% | +$373K |
|
3025
Invesco KBW Bank ETF
KBWB
$6.84B
| $1.69M | ﹤0.01% |
20,000
+13,482
| +207% | +$1.07M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.